Cargando…
Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)(†)
BACKGROUND: There is no standard first-line chemotherapy for advanced urothelial carcinoma (aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the efficacy and tolerability profile of two vinflunine-based cytotoxic regimens in this setting. PATIENTS AND METHODS: Patients wit...
Autores principales: | De Santis, M., Wiechno, P. J., Bellmunt, J., Lucas, C., Su, W.-C., Albiges, L., Lin, C.-C., Senkus-Konefka, E., Flechon, A., Mourey, L., Necchi, A., Loidl, W. C., Retz, M. M., Vaissière, N., Culine, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769994/ https://www.ncbi.nlm.nih.gov/pubmed/26673352 http://dx.doi.org/10.1093/annonc/mdv609 |
Ejemplares similares
-
Vinflunine in the treatment of bladder cancer
por: Bachner, Mark, et al.
Publicado: (2008) -
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
por: Culine, S, et al.
Publicado: (2006) -
The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine
por: Harshman, L C, et al.
Publicado: (2013) -
Stathmin Potentiates Vinflunine and Inhibits Paclitaxel Activity
por: Malesinski, Soazig, et al.
Publicado: (2015) -
Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
por: Bernardini, Alejandra, et al.
Publicado: (2022)